ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

Successful Treatment by Community MDs Reducing Numbers Of Patients In Research, DCT Board Told; “We can Work With them,” Carbone Says

April 27, 1979

In Brief: U – South Western Wins BMS Grant; ONS Gets $1.6 M; Unilever Chair In Diet Formed At CINJ

May 7, 1999

DCE Advisors OK Recompetitions Worth $10 Mil.

July 19, 1991

Dexamethasone Improved Survival Of Leukemia

November 26, 2004

Sexual Function Affected By Stem Cell Transplant

September 28, 2007

New Drug Approval: Groups Urge FDA To Move Quickly On Herceptin Approval

September 18, 1998